Whalestream has ceased operations permanently
Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 08/21/2026 | PUT | $35.00 | 5,779 | +1,204 | +26.32% |
| 07/02/2026 | CALL | $49.50 | 1,650 | +1,087 | +193.07% |
| 09/18/2026 | PUT | $40.00 | 24,612 | +764 | +3.20% |
| 12/17/2027 | CALL | $90.00 | 2,688 | +735 | +37.63% |
| 07/02/2026 | CALL | $49.00 | 1,705 | +636 | +59.49% |
| 12/17/2027 | CALL | $70.00 | 7,109 | +580 | +8.88% |
| 07/02/2026 | PUT | $44.00 | 3,519 | -92 | -2.55% |
| 01/21/2028 | PUT | $50.00 | 3,257 | -109 | -3.24% |
| 09/18/2026 | CALL | $45.00 | 12,696 | -238 | -1.84% |
| 07/02/2026 | PUT | $52.00 | 22 | -283 | -92.79% |
| 12/18/2026 | CALL | $70.00 | 1,916 | -296 | -13.38% |
| 07/02/2026 | CALL | $48.00 | 4,742 | -319 | -6.30% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Harbor Capital Appreciation Fund | 0.18% | 3.11M | 481.53M |
| Washington Mutual Investors Fund | 0.09% | 1.51M | 234.45M |
| Vanguard U.S. Growth Fund | 0.07% | 1.27M | 196.47M |
| Loomis Sayles Growth Fund | 0.07% | 1.18M | 183.13M |
| Fidelity Blue Chip Growth Fund | 0.07% | 1.13M | 175.35M |
| Amana Mutual Funds Trust-Growth Fund | 0.06% | 1M | 155.09M |
| PGIM Jennison Growth Fd | 0.05% | 828.11k | 128.15M |
| Blackrock Equity Dividend Fund | 0.04% | 712k | 110.18M |
| New Perspective Fund Inc | 0.04% | 691.44k | 107M |
| Price (T.Rowe) International Stock Fund | 0.04% | 674k | 104.3M |
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
07/08 05:21 pm
The Motley Fool
Read moreIs It Too Late to Buy Eli Lilly?
07/08 02:10 pm
The Motley Fool
Read morePrediction: Eli Lilly Stock Will Hit This Price by the End of 2026
07/08 08:30 am
The Motley Fool
Read moreEli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
07/07 05:30 pm
The Motley Fool
Read moreHims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand
07/07 11:37 am
Investing.com
Read moreIs It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.
07/07 08:10 am
The Motley Fool
Read moreEli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
07/06 01:09 pm
The Motley Fool
Read moreCould This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
07/06 07:15 am
The Motley Fool
Read moreHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
07/05 01:05 am
The Motley Fool
Read moreIs Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying
07/04 05:10 am
The Motley Fool
Read moreJohnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
07/03 09:15 pm
The Motley Fool
Read moreHere's Why Viking Therapeutics Stock Surged Higher in June
07/03 09:25 am
The Motley Fool
Read moreBig Pharma Has a Case of Merger Mania
06/30 12:26 am
The Motley Fool
Read more2 Top Growth Stocks to Buy Right Now Without Hesitation
06/29 05:10 am
The Motley Fool
Read moreOpinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
06/27 03:15 pm
The Motley Fool
Read moreIs Eli Lilly Stock an Undervalued Healthcare Stock to Buy?
06/26 08:15 pm
The Motley Fool
Read moreDyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
06/26 11:05 am
The Motley Fool
Read moreAn Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
06/25 11:18 am
The Motley Fool
Read moreZealthy Expands Insurance Coordination for GLP-1 Weight-Loss Medications
06/23 04:52 pm
GlobeNewswire Inc.
Read moreTheDoseReport Announces Which GLP-1 is Best? Semaglutide and Tirzepatide
06/21 07:33 am
GlobeNewswire Inc.
Read moreIntellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
06/20 11:02 am
The Motley Fool
Read more3 Under-the-Radar Stocks to Buy and Hold for a Decade
06/16 03:30 am
The Motley Fool
Read moreNovo Nordisk’s Wegovy Pill Turns Pricing Pain Into a Volume Bet
06/15 02:07 pm
Investing.com
Read more3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
06/14 08:15 am
The Motley Fool
Read morePfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
06/12 12:32 pm
The Motley Fool
Read moreIs Viking Therapeutics Stock Going to $100?
06/12 01:15 am
The Motley Fool
Read moreNovo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
06/11 01:34 pm
Benzinga
Read moreWhy 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
06/10 01:27 pm
The Motley Fool
Read moreNxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
06/10 02:35 am
GlobeNewswire Inc.
Read moreA Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
06/08 12:14 pm
The Motley Fool
Read moreNovo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs
06/08 08:55 am
Benzinga
Read moreNovo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
06/06 09:15 am
The Motley Fool
Read moreEli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
06/04 09:27 am
The Motley Fool
Read moreLilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors
05/30 08:15 am
The Motley Fool
Read moreThe Smartest Growth Stocks to Buy With $2,000 Right Now
05/30 06:15 am
The Motley Fool
Read moreContrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
05/28 12:15 pm
The Motley Fool
Read morePresident Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
05/27 02:02 pm
The Motley Fool
Read morePrediction: These 2 Obesity Drug Stocks Could Double in 2026
05/26 04:04 am
The Motley Fool
Read moreEli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
05/25 07:15 pm
The Motley Fool
Read moreEli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
05/25 05:05 am
The Motley Fool
Read moreIs Viking Therapeutics a Top Takeover Target?
05/23 04:31 pm
The Motley Fool
Read moreThe Most Important Healthcare Stock You're Not Watching
05/22 05:15 pm
The Motley Fool
Read moreNovo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
05/22 01:30 pm
GlobeNewswire Inc.
Read moreFrom Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
05/21 10:43 am
Investing.com
Read moreBest Weight Loss Drug Stocks to Buy in 2026
05/20 11:15 pm
The Motley Fool
Read more